Yuhan Corporation Appoints Kim Yeolhong, Professor at Korea University College of Medicine, as President in Charge of R&D

Yuhan Corporation announced on the 3rd that it has appointed Professor Kim Yeolhong, an oncologist and hematologist at Korea University College of Medicine, as the president in charge of research and development (R&D).

Kim Yeon-hong, President in charge of R&D at Yuhan Corporation, is delivering an inaugural speech. [Photo by Yuhan Corporation]

President Kim Yeolhong graduated from Korea University College of Medicine and earned his master's and doctoral degrees from the same institution. He has dedicated himself to cancer research and treatment while serving as a professor in the Department of Oncology and Hematology at Korea University Anam Hospital. Additionally, he has held positions such as Director of the Genomic Research Centers for Lung, Breast, and Ovarian Cancers designated by the Ministry of Health and Welfare, President of the Korean Society of Genomics, Director of the Cancer Center at Korea University Anam Hospital, Chairman of the Korean Cancer Association, and President of the Asian Cancer Association.

In particular, he led the Korea University Cancer Diagnosis and Treatment Development Project Group (K-MASTER) as its director, building data and expertise related to precision medicine for cancer. Based on this experience, he founded OncoMaster, a precision medicine platform company for cancer patients, and has worked to expand patient accessibility as an expert in cancer diagnostics and therapeutics, Yuhan Corporation explained.

Yuhan Corporation expects that by recruiting President Kim, it will be able to further strengthen its R&D capabilities focused on tumor-related disease groups. Tumors, metabolic diseases, and the central nervous system (CNS) are the three strategic disease groups where Yuhan is concentrating its research resources and capabilities.

Approaching its 100th anniversary in 2026, Yuhan Corporation developed 'Reclaza' (generic name: Lazertinib), the 31st new drug in Korea, for the treatment of non-small cell lung cancer. In addition, it is operating more than 30 new drug pipelines, including immuno-oncology agents.